Navigation Links
Emmaus Life Sciences Announces Closing Of $7.5 Million Private Placement
Date:9/16/2013

TORRANCE, Calif., Sept. 16, 2013 /PRNewswire/ -- Emmaus Life Sciences, Inc. (the "Company," or "Emmaus"), a biotherapeutics company dedicated primarily to the discovery, development and commercialization of innovative and cost effective treatments and therapies for debilitating rare diseases, today announced it has raised approximately $7.5 million in gross proceeds from a private placement to accredited investors, including two institutional investors.

In connection with the financing, Emmaus has agreed to expand its board of directors to eight members, with three newly-created directorships to be filled by qualified representatives of certain participants in the financing.

The net proceeds from the private placement will be used primarily for research and development, including the completion of the company's Phase 3 clinical trial for the treatment of sickle cell disease, commercialization costs, and for working capital and general corporate purposes.

T.R. Winston & Company served as placement agent to Emmaus.

The shares of common stock and warrants described above were offered and sold to a limited number of institutional and accredited investors. The shares of common stock and warrants, and the shares of common stock issuable upon exercise of the warrants, have not been registered under the Securities Act of 1933, as amended, or applicable state securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state securities laws.

This press release is issued pursuant to Rule 135(c) under the Securities Act and shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful.

About Emmaus Life Sciences

Emmaus is dedicated to the discovery, development and commercialization of innovative and cost-effective treatments and therapies for rare diseases.

For more information, please visit www.emmauslifesciences.com.

Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and potential commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. Additional risks and uncertainties are described in reports filed by Emmaus Life Sciences, Inc. with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2012. Emmaus is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

Contacts:

Media:

Lori Teranishi for Emmaus Life Sciences, Inc.
415-981-1964
lteranishi@iqprinc.com

Investors:

Matt Sheldon for Emmaus Life Sciences, Inc.
310-279-5975
msheldon@pondel.com


'/>"/>
SOURCE Emmaus Life Sciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Garage Start-ups Now Possible in Life Sciences Industry
2. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
3. DiaTech Life Sciences Announces Medical Advisory Board
4. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
5. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference
6. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
7. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
8. At-the-Market Offerings (ATM) of Life Sciences Companies Perform Well in Weak Follow-on Financing Environment of Third Quarter
9. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
10. Islet Sciences, Inc. Selects NeoStems Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing
11. Elsevier Acquires QUOSA, Provider of Life Sciences Content Management and Workflow Productivity Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017  GlobeImmune, Inc. today ... for the sale of 12,835,490 shares of its common ...  ecosystem of companies. In connection with the sale of its ... in cash and issue to GlobeImmune 200,000 shares, an ... "We are pleased to enter into ...
(Date:3/23/2017)... 23, 2017 Kineta, Inc., a biotechnology ... therapies in immuno-oncology, today announced the discovery and ... compounds that activate interferon response factor 3 (IRF3) ... immune-mediated tumor regression in a murine colon carcinoma ... demonstrated complete tumor regression to initial drug treatment ...
(Date:3/23/2017)... , March 23, 2017  Agriculture technology company Cool ... financing and note conversion to commercialize its Cool Terra ... focused on developing products that are simultaneously profitable as ... in the last 18 months. This latest round of ... Venture Partners. The company,s primary product, ...
(Date:3/22/2017)... Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced a major research ... GSK to generate genetic sequence data from the 500,000 volunteer ... researchers to gain valuable insights to support advances in the ... and life threatening diseases. ... Genetic evidence has revolutionized scientific discovery ...
Breaking Biology Technology:
(Date:3/20/2017)... , March 20, 2017 PMD Healthcare ... personal spirometer and Wellness Management System (WMS), a remote, ... Founded in 2010, PMD Healthcare is a Medical Device, ... a mission dedicated to creating innovative solutions that empower ... With that intent focus, PMD developed the first ever ...
(Date:3/9/2017)... Australia , March 9, 2017 /PRNewswire/ ... at the prestigious World Lung Imaging Workshop at the ... Fouras , was invited to deliver the latest data ... This globally recognised event brings together leaders at the ... latest developments in lung imaging. "The ...
(Date:3/7/2017)... 2017   HireVue , the leading provider of ... the best talent, faster, today announced the additions of ... and Diana Kucer as Chief Marketing Officer ... team poised to drive continued growth in the company,s ... of record bookings in 2017. "Companies worldwide ...
Breaking Biology News(10 mins):